STF-62247 Struktur

STF-62247

Bezeichnung:STF-62247

CAS-Nr315702-99-9

Englisch Name:STF-62247

CBNumberCB82526236

SummenformelC15H13N3S

Molgewicht267.35

MOL-Datei315702-99-9.mol

STF-62247 physikalisch-chemischer Eigenschaften

Schmelzpunkt	158-160℃
Dichte	1.255
storage temp.	Keep in dark place,Sealed in dry,Room Temperature
Löslichkeit	DMSO: soluble26mg/mL
Aggregatzustand	solid
Farbe	Off-white
Stabilität	Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.

Sicherheit

Kennzeichnung gefährlicher	Xn
R-Sätze:	22-36
S-Sätze:	26-39
WGK Germany	2

Gefahreninformationscode (GHS)

STF-62247 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
STF-62247 (315702-99-9) specifically induces autophagic cell death in VHL (von Hippel-Lindau)-deficient renal carcinoma cells both in vitro (IC50=625 nM) and in vivo. Renal cell carcinoma cell lines were radiosensitized by induction of autophagy following treatment with STF-62247. Cell permeable
Verwenden
Autophagy Inducer, STF-62247 is selectively kills RCC cells that have lost VHL tumor suppressor activity.
Definition
ChEBI: N-(3-methylphenyl)-4-pyridin-4-yl-2-thiazolamine is a substituted aniline.
in vitro
in vitro study demonstrated that stf-62247 exhibited selectively cytotoxicity and tumor growth inhibitory activity towards wild-type vhl and vhl-deficient renal cell carcinoma (rcc) in a hif-independent manner with ic50 of 16 μm and 0.625 μm, respectively. in addion, stf-62247 also resulted in cell apoptosis by inducing acidification and increasing autophagy in vhl-deficient cells. [1]
in vivo
animal experiments for stf-62247 activity were performed according to institutional and national guidelines and approved by stanford university's administrative panel on laboratory animal care. based on an in vivo mouse model, it was found that intraperitoneal injection of stf-62247 at a dose of 8 mg/kg significantly inhibited tumor growth of vhl-deficient sn12c tumor cells. [1]
IC 50
stf-62247 inhibits tumor growth in wild-type vhl and vhl-deficient renal cell carcinoma (rcc) in a hif-independent manner with ic50 of 16 μm and 0.625 μm, respectively.
Einzelnachweise
1) Turcotte et al. (2008), Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death; Autophagy, 4 944 2) Chan et al. (2008), Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics; Cell Cycle, 7 2987 3) Anbalagan et al. (2012), Radiosensitization of renal cell carcinoma in vitro through the induction of autophagy; Radiother. Oncol., 103 388

STF-62247 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

315702-99-9, STF-62247 Verwandte Suche:

Send Inquriy